Physician's Weekly Podcast

Global Wildfires and Human Health; Teprotumumab for Dysthyroid Optic Neuropathy

December 08, 2021 Physician's Weekly Season 1 Episode 32
Physician's Weekly Podcast
Global Wildfires and Human Health; Teprotumumab for Dysthyroid Optic Neuropathy
Show Notes

Roman Shinder, MD from the Department of Ophthalmology at SUNY Downstate Medical Center in New York, on initial data at the 2021 Fall Scientific Symposium of the American Society of Ophthalmic Plastic and Reconstructive Surgery, held in New Orleans from November 11 to 12, 2021 looking at efficacy of teprotumumab as monotherapy for the treatment of dysthyroid optic neuropathy [1].

Yuming Guo, MD PhD, Professor of Global Environmental health at Monash University, in Australia, about the link with global wildfires to human health, which was published in the New England Journal of Medicine and the Lancet Planet Health [2,3].

Alexander Blood, MD, from Brigham and Women’s Hospital, Massachusetts, the first author of the current study, about his presentation at the late-breaking session at the American Heart Association Scientific Sessions held Nov 13-15, 2021 [4], on an ongoing remote digital care program to manage hypertension and hypercholesterolemia 


Further reading:

1.      Artymowicz A, Shinder R. Teprotumumab as monotherapy for dysthyroid optic neuropathy. Poster presented at: American Society of Ophthalmic Plastic & Reconstructive Surgery 2021 Annual Meeting; November 12-15, 2021; New Orleans, LA.

2.      Xu R, Yu P, Abramson MJ, Johnston FH, Samet JM, Bell ML, Haines A, Ebi KL, Li S, Guo Y. Wildfires, Global Climate Change, and Human Health. N Engl J Med. 2020 Nov 26;383(22):2173-2181. 

3.      Chen G, Guo Y, et al. Mortality risk attributable to wildfire-related PM2·5 pollution: a global time series study in 749 locations. Lancet Planet Health. 2021 Sep;5(9):e579-e587

4.      Blood AJ, et al. Digital Care Transformation: Report from the First 10,000 Patients Enrolled in a Remote Algorithm-based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control. LBS02, AHA Scientific Sessions 2021, 13–15 November.